

# John Anderson Wells, III, MD, FACS

Palmetto Retina Center  
124 Sunset Court  
West Columbia, SC, 29169 USA  
Ph. 803-931-0077  
Fax 803-931-0076  
Email [jackwells@palmettoretina.com](mailto:jackwells@palmettoretina.com)

## PERSONAL

Born September 17, 1960, Charleston, South Carolina  
Married to Elizabeth Vardell Wells, 4 children

## EDUCATION

1974-78 Hammond School, Columbia, South Carolina, valedictorian  
1978-82 Washington and Lee University, Lexington, Virginia, Bachelor of  
Science, Biology, *magna cum laude*  
1982-86 Emory University School of Medicine, Atlanta, Georgia, Doctor of  
Medicine

## POSTGRADUATE EDUCATION

1986-88 Intern and Resident, Internal Medicine, Emory University  
Affiliated Hospitals, Atlanta, Georgia  
1988-91 Resident, Ophthalmology, Emory University Affiliated Hospitals,  
Atlanta, Georgia  
1991-92 Fellow, Medical Retina, Moorfields Eye Hospital, London,  
England with Professor Alan Bird  
1994-95 Fellow, Vitreoretinal Surgery, Moorfields Eye Hospital, London,  
England with Mr. Zdenek Gregor

## PRACTICE HISTORY

1992-94 General Ophthalmology Private Practice, Columbia, SC  
1995-99 Carolina Eye Consultants, LLC, Practice limited to diseases and  
surgery of the retina and vitreous, Columbia, SC  
2000 Assistant Professor of Ophthalmology, Vitreoretinal Diseases and  
Surgery, Department of Ophthalmology, University of South  
Carolina School of Medicine, Columbia, SC  
2001 – Palmetto Retina Center, LLC, Practice limited to diseases and  
surgery of the retina and vitreous, Columbia, SC

## HONORS AND ACTIVITIES

1980-82 Student Government, Washington and Lee University  
1982 Omicron Delta Kappa, Washington and Lee University  
1981 Phi Beta Kappa, Washington and Lee University  
1984-86 Admissions Committee, Emory University School of Medicine

## John Anderson Wells, III

- 1986-91 Class Agent, Emory University School of Medicine Alumni Association
- 1995 Participant, Columbia Medical Society Mini-Internship Program
- 1996-97 Executive Committee, South Carolina Society of Ophthalmology
- 1998-99 Secretary, Medical Journal Club
- 2000 Vice-President, Medical Journal Club
- 2001 President, Medical Journal Club
- 2000-02 Class Agent, Washington and Lee University Annual Fund
- 2005 Participant, Leadership Development Program, American Academy of Ophthalmology
- 2006-10 Member, Secretariat for State Affairs, American Academy of Ophthalmology
- 2007 25<sup>th</sup> Reunion Committee, Washington and Lee University
- 2009-12 Class Agent, Washington and Lee University Annual Fund
- 2009-13 Executive Committee, Age-Related Eye Disease Study 2
- 2010- Congressional Advocate, Federal Advocacy Program, American Academy of Ophthalmology
- 2010 Achievement Award, American Academy of Ophthalmology
- 2011-15 Protocol Chair, A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema, Diabetic Retinopathy Clinical Research Network
- 2012-13 President, South Carolina Society of Ophthalmology
- 2012-15 Executive Committee, Diabetic Retinopathy Clinical Research Network
- 2012-15 Operations Group, Diabetic Retinopathy Clinical Research Network
- 2013-15 Vice-Chair, Diabetic Retinopathy Clinical Research Network
- 2013- Member, OPHTHPAC Committee, American Academy of Ophthalmology

## PROFESSIONAL ORGANIZATIONS

- 1982- Member, American Medical Association
- 1988-92 Member, American Academy of Ophthalmology
- 1991- Member, Emory Eye Alumni Association
- 1992- Fellow, American Academy of Ophthalmology
- 1992- Member, Oxford Ophthalmological Society,
- 1992- Member, Moorfields Eye Hospital Alumni Association
- 1992- Member, South Carolina Medical Association
- 1992- Member, Columbia Medical Society
- 1992- Member, Central South Carolina Ophthalmological Society
- 1992- Member, South Carolina Society of Ophthalmology
- 1995- Member, Association for Research in Vision and Ophthalmology
- 1988-00 Associate Member, American College of Surgeons
- 2000- Fellow, American College of Surgeons
- 2000- Member, American Society of Retinal Specialists
- 2012- Member, Club Jules Gonin
- 2012- Member, The Retina Society
- 2013- Member, The Macula Society

## BOARD CERTIFICATION

John Anderson Wells, III

1993 American Board of Ophthalmology  
2003 Recertified, American Board of Ophthalmology  
2013 Recertified, American Board of Ophthalmology

### **HOSPITAL APPOINTMENTS**

1992-2014 Providence Hospital, Columbia, SC  
Chief, Department of Ophthalmology 1994  
Vice-Chief, Department of Ophthalmology 2003  
Chief, Department of Ophthalmology 2004-2005  
1992- Palmetto Richland Memorial Hospital, Columbia, SC  
Chief, Department of Ophthalmology, 1996  
1992- Palmetto Baptist Medical Center, Columbia, SC  
1992-02 VA Medical Center, Columbia, SC  
2001- Lexington Medical Center, West Columbia, SC

### **ACADEMIC APPOINTMENTS**

1992-98 Clinical Instructor, Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA  
1992-99 Clinical Assistant Professor, Department of Ophthalmology, University of South Carolina School of Medicine, Columbia, SC  
2000 Assistant Professor, Department of Ophthalmology, University of South Carolina School of Medicine, Columbia, SC  
2005- Clinical Associate Professor of Ophthalmology, Department of Ophthalmology, University of South Carolina School of Medicine, Columbia, SC  
2013-15 Interim Chairman, Department of Ophthalmology, University of South Carolina School of Medicine and Palmetto Health System, Columbia, SC  
2015- Chairman, Department of Ophthalmology, Palmetto Health/USC School of Medicine, Columbia, SC

### **ABSTRACTS**

Seedor JA, Walsh GE, **Wells JA**, et al. Corneas from ventilator supported donors: endothelial morphology and results of a survey. Eye Bank Association of America Abstracts, November 1987.

Holz FG, Wolfensberger TJ, Piguet B, **Wells JA**, et al. Bilateral macular drusen in age-related macular degeneration: prognosis and risk factors. American Academy of Ophthalmology Annual Meeting 1993, Program Abstracts, p. 62.

Wolin MJ, **Wells JA**. Acute zonal occult outer retinopathy. North American Neuro-ophthalmology Society Abstracts, February 1994.

John Anderson Wells, III

Pitts JF, Schwartz SD, **Wells JA**, Gregor ZJ. Trans-scleral indirect argon laser drainage of subretinal fluid. The Royal College of Ophthalmologists Annual Meeting Abstracts, May 1995, p. 96.

**Wells JA**, Gray RH, Kinsella F, Orr GM, Arden GB, Gregor ZJ. Fellow eye involvement in patients with macular holes: incidence and identification of eyes at risk. American Academy of Ophthalmology Annual Meeting 1995, Program Abstracts, p. 148.

Gregor ZJ, Ruckmann AV, Schmidt KG, **Wells J**. Diagnosing and staging of macular holes using autofluorescence imaging. ARVO Abstracts, April 1996.

Ezra E, **Wells JA**, Charteris DG, Aylward GW, Gregor ZJ. Macular hole surgery with and without autologous serum: a prospective study of 109 consecutive eyes. ARVO Abstracts, April 1996.

Boada R, Cady R, **Wells JA**, Clark WL, Goins C, Saperstein D. Tissue plasminogen activator (t-PA) assisted subfoveal hemorrhage displacement surgery. ARVO Abstracts May 2002.

Wroblewski JJ, **Wells III JA**, Gonzales CR, Clark WL, Schwartz SD. Pegaptanib for the treatment of macular edema secondary to branch retinal vein occlusion: interim results of an open label study. 25<sup>th</sup> Annual Meeting, American Society of Retinal Specialists Program Summary Indian Wells, California, December 3, 2007.

## **ORAL PRESENTATIONS**

**Wells JA**, Sternberg P, Meredith TA. Acute dappled pigment epitheliopathy. Residents' Day, Emory Eye Center, Atlanta, June 1990.

**Wells JA**, Sternberg P, Stulting RD. Pseudomonas scleritis and keratoscleritis. Residents' Day, Emory Eye Center, Atlanta, June 1991.

**Wells JA**. Recent advances in the genetics of retinal degenerations. Grand Rounds, South Carolina Eye Institute, Columbia, December 1992.

**Wells JA**, Bird AC. Retinal degenerations and the peripherin-RDS gene. Lecture, Duke Eye Center, Durham, February 1993.

**Wells JA**. Retinitis pigmentosa: new genetic findings. Southeastern Genetic Cytotechnologists Meeting, Columbia, September 1993.

**Wells JA**. Major eye diseases of the elderly. South Carolina Commission for the Blind Seminar, Columbia, November 1993.

**Wells JA**. Acute zonal occult outer retinopathy. Eighth Southeastern Vitreoretinal Seminar, Atlanta, February 1994.

**Wells JA**. Laser treatment of subretinal neovascularization. Grand Rounds, South Carolina Eye Institute, Columbia, May 1994.

**Wells JA**, Gregor ZJ. Idiopathic full-thickness macular holes. Vitreoretinal Teaching Conference, Moorfields Eye Hospital, London, September 1994.

**Wells JA**, Hiscott PA, Luthert P, Gregor ZJ. Surgical removal of subfoveal membranes. Moorfields Alumni Meeting, London, January 1995.

**Wells JA**, Gregor ZJ. The vanishing nucleus: management of dislocated crystalline lenses. Moorfields Eye Hospital Grand Rounds, London, February 1995.

John Anderson Wells, III

**Wells JA, Gregor ZJ.** Laser treatment of retinal disease. City College Optometry Course, London, February 1995.

**Wells JA, Chibber R, Kohner E, Gregor ZJ.** Vascular endothelial growth factor/ vascular permeability factor (VEGF/VPF) levels are elevated in the vitreous of patients with subretinal neovascularization. ARVO Annual Meeting, Fort Lauderdale, FL, May 1995.

**Wells JA, Gregor ZJ.** Surgical treatment of full-thickness macular holes using autologous serum. Royal College of Ophthalmologists Annual Meeting, Birmingham, May 1995.

**Wells JA.** Reticular pseudodrusen in age-related macular degeneration. The Royal Australian College of Ophthalmologists (Victorian Branch) Annual Scientific Meeting, Portsea, Victoria, Australia, March 10, 2000.

**Wells JA.** Fundus autofluorescence in macular diseases. Bert M. Glaser National Retina Institute Feeder Vessel Treatment of CNV Seminar, New York City, NY, June 2002

**Wells JA, Clark WL, Wroblewski JJ.** Inferior displacement of submacular hemorrhage. XXIII Meeting of the Club Jules Gonin, Lausanne, Switzerland, September 2002.

**Wells JA.** Understanding age-related macular degeneration. Palmetto Health Baptist Hospital Continuing Medical Education Lunch & Learn, Columbia, SC, October 16, 2003.

**Wells JA.** Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion. 24<sup>th</sup> Annual Meeting of the American Society of Retina Specialists, Cannes, France, September 12, 2006.

**Wells JA** for the Pegaptanib in Central Retinal Vein Occlusion Study Group. Treatment of macular edema following central retinal vein occlusion with pegaptanib sodium. Combined Meeting of The Club Jules Gonin and The Retina Society, Cape Town, South Africa, October 16, 2006.

**Wells JA.** Pegaptanib sodium (Macugen) for the treatment of macular edema following central retinal vein occlusion (CRVO). Ninth Michaelson Symposium, Baltimore, MD, May 1, 2007.

**Wells III JA, Wroblewski JJ,** for the Macugen in CRVO Study Group. Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): functional outcomes. ARVO Annual Meeting, Fort Lauderdale, FL, May 7, 2007.

**Wells JA.** American Academy of Ophthalmology Update. Georgia Society of Ophthalmology Annual Meeting, Sea Island, GA, July 29, 2007.

**Wells JA, Wroblewski JJ,** for the Pegaptanib in Central Retinal Vein Occlusion Study. Safety and efficacy of pegaptanib sodium in the treatment of macular edema secondary to central retinal vein occlusion. 25<sup>th</sup> Annual Meeting, American Society of Retinal Specialists, Indian Wells, California, December 3, 2007.

**Wells JA, Adamis AP, Berman AJ et al.** A phase 1 open-label study of single and repeated doses of intravitreal JSM6427, a small molecule integrin  $\alpha_5\beta_1$  antagonist, in neovascular age-related macular degeneration (AMD). XXVIth Meeting of The Club Jules Gonin, St. Moritz, Switzerland, September 11, 2008.

**Wells III JA, Gonzalez VH, Heier JS, et al.** A phase 1 dose escalation study of intravitreal JSM6427, an integrin  $\alpha_5\beta_1$  antagonist, in neovascular AMD. American Academy of Ophthalmology Annual Meeting, Atlanta, GA, Nov 11, 2008.

Capone A, Gonzalez VH, Heier JS, **Wells III JA,** et al. A phase 1 open-label study of single and repeated doses of intravitreal JSM6427, a small molecule integrin  $\alpha_5\beta_1$  antagonist, in neovascular age-related macular degeneration (AMD). ARVO Annual Meeting, Fort Lauderdale, FL, May 4, 2009.

**Wells JA** for the Diabetic Retinopathy Clinical Research Network. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. American Academy of Ophthalmology Annual Meeting, San Francisco, CA, October 25, 2009.

**Wells JA** for the Diabetic Retinopathy Clinical Research Network. Number of laser-ranibizumab-triamcinolone treatments for diabetic macular edema (DME). 28<sup>th</sup> Annual Meeting of the American Society of Retina Specialists, Vancouver, BC, Canada, August 29, 2010.

Bressler NB, Arevalo F, Avila MP, Lim JI, Ohji M, Schwartz SD, **Wells JA**. DRCR Network Panel Discussion on Diabetic Macular Edema, AAO Retina Subspecialty Day, Chicago, IL, October 16, 2010.

**Wells III JA** for the Diabetic Retinopathy Clinical Research Network. Number of laser-ranibizumab-triamcinolone treatments for diabetic macular edema. XXVIIth Meeting of The Club Jules Gonin, Kyoto, Japan, November 6, 2010.

**Wells JA** for the CATT Research Group. Ranibizumab and Bevacizumab for neovascular AMD. Age-Related Macular Degeneration: Fundamental Aspects and Translation into New Treatments. V. International DOG Symposium Sept 8-10, 2011, Baden-Baden, Germany.

**Wells J** for the ICONIC study group. Multi-center phase 1 clinical trial targeting tissue factor for the treatment of neovascular age-related macular degeneration. Retina Society Annual Meeting, Washington DC, Oct 6<sup>th</sup> 2012. (Substitute presenter Stephen Schwartz, MD)

**Wells JA** for the Diabetic Retinopathy Clinical Research Network. Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt vs. Deferred Laser Treatment: 5-year Randomized Trial Results. American Society of Retinal Specialists 32<sup>nd</sup> Annual Meeting, San Diego, CA, August 11, 2014.

**Wells JA**. Unilateral Retinoschisis. XXIXth Meeting of the Club Jules Gonin, Zurich, Switzerland, September 3, 2014.

**Wells JA** for the Ophthotech Study Group. Role of PDGF Antagonism and Development of Subretinal Fibrosis in a Phase 2, Randomized, Double Masked, Controlled Trial of Intravitreal Injections of Fovista (anti-PDGF pegylated aptamer) administered in combination with Lucentis in subjects with Neovascular Age-Related Macular Degeneration. XXIXth Meeting of the Club Jules Gonin, Zurich, Switzerland, September 4, 2014.

**Wells JA**. Recurrent Punctate Inner Choroidopathy. Macula Society 38<sup>th</sup> Annual Meeting, Scottsdale, AZ, February 25, 2015.

**Wells JA** for the Diabetic Retinopathy Clinical Research Network. Comparison of Visual and OCT Outcomes in Eyes with and without Prior Vitrectomy Receiving Anti-Vascular Endothelial Growth Factor Treatment in a Randomized Trial Evaluating Ranibizumab with Prompt or Deferred Laser for Diabetic Macular Edema. Macula 2015, Boston, MA, January 10, 2015.

**Wells JA** for the Diabetic Retinopathy Clinical Research Network. Comparative Effectiveness Randomized Clinical Trial of Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. Macula Society 38<sup>th</sup> Annual Meeting, Scottsdale, AZ, February 26, 2015.

**Wells JA** for the Diabetic Retinopathy Clinical Research Network. Comparative Effectiveness Randomized Clinical Trial of Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. National Advisory Eye Council Meeting, National Eye Institute, Bethesda, MD, June 4, 2015.

**Wells JA** for the Diabetic Retinopathy Clinical Research Network. Comparative Effectiveness Randomized Clinical Trial of Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. American Academy of Ophthalmology Annual Meeting, Retina Subspecialty Day, Las Vegas, NV, November 13, 2015.

**Wells JA** for the Diabetic Retinopathy Clinical Research Network. Comparative Effectiveness Randomized Clinical Trial of Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. American Academy of Ophthalmology Annual Meeting, Best of Subspecialty Session, Las Vegas, NV, November 15, 2015.

**Wells JA** for the Diabetic Retinopathy Clinical Research Network. Comparative Effectiveness Randomized Clinical Trial of Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. American Academy of Ophthalmology Annual Meeting, Diabetic Retinopathy Clinical Research Network Instruction Course, Las Vegas, NV, November 17, 2015.

**Wells JA** for the Diabetic Retinopathy Clinical Research Network. Comparative Effectiveness Randomized Clinical Trial of Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. Retina Symposium 2016. Amsterdam, Netherlands, January 10, 2016.

**Wells JA** for the Diabetic Retinopathy Clinical Research Network. Comparative Effectiveness Randomized Clinical Trial of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema: Two Year Results. Macula Society, Miami Beach, FL, February 27, 2016.

**Wells JA** for the OPHTHPAC of the American Academy of Ophthalmology. EHR Meaningful Use Improvements. AAO Congressional Advocacy Day, Washington, DC, April 13, 2016.

**Wells JA** for the Diabetic Retinopathy Clinical Research Network. Comparative Effectiveness Randomized Clinical Trial of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema: Two Year Results. ARVO 2016, Seattle, WA, May 2, 2016.

## **POSTER PRESENTATIONS**

**Wells JA**, McCarey BE. Three-year morphological follow-up of hydrogel intracorneal implants. ARVO Annual Meeting, Sarasota, May 1987.

Pitts JF, Schwartz SD, **Wells JA**, Gregor ZJ. Trans-scleral indirect argon laser drainage of subretinal fluid. The Royal College of Ophthalmologists Annual Meeting, Birmingham, May 1995.

**Wells JA**, Grey RB, Arden GB, Gregor ZJ. Fellow eye macular holes: incidence and risk factors. American Academy of Ophthalmology Annual Meeting, Atlanta, October 1995.

**Wells JA**, Ezra EM, Gregor ZJ. Incidence of full-thickness macular holes in fellow eyes: a prospective five year study. XXI Meeting of the Club Jules Gonin, September 1998.

**Wells JA.** Reticular pseudodrusen in age-related macular degeneration. XXII Meeting of the Club Jules Gonin, Taormina, Sicily, September 2000.

**Wells JA** for the Pegaptanib in Central Retinal Vein Occlusion Study Group. Safety and efficacy of pegaptanib sodium in treating macular edema secondary to central retinal vein occlusion. American Academy of Ophthalmology Annual Meeting, Las Vegas, NV, November 12, 2006.

Wroblewski JJ, **Wells JA**, Gonzales C. Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion (BRVO). ARVO Annual Meeting, Fort Lauderdale, FL, April 29, 2008.

**Wells III JA**, Driver M. Treatment of diabetic macular edema (DME) with pegaptanib sodium (Macugen): a case series. ARVO Annual Meeting, Fort Lauderdale, FL, May 4, 2009.

**Wells JA**, Driver MC. Pegaptanib sodium (Macugen) in the treatment of diabetic macular edema (DME): a case series from two clinical practices. Retina Congress 2009 New York: A Combined Meeting of the American Society of Retina Specialists, The Retina Society and the Macula Society. New York, NY, Oct 1, 2009.

**Wells J** for the Diabetic Retinopathy Clinical Research Network: Factors associated with changes in visual acuity and OCT thickness at one year after treatment with ranibizumab for DME. American Society of Retinal Specialists 29<sup>th</sup> Annual Meeting, Boston, MA, August 21-24, 2011

Katz B and **Wells JA.** Failure of intravitreal bevacizumab therapy for neovascular AMD followed by successful response to intravitreal ranibizumab. ARVO Annual Meeting, Fort Lauderdale, FL, May 1, 2011.

**Wells JA**, Berger BB, Gonzales C, Gonzales BH, Johnson DL, Sippy BD, Soni M. Multicenter phase 1 clinical trial targeting tissue factor for the treatment of neovascular AMD. ARVO Annual Meeting, Fort Lauderdale, FL, May 6<sup>th</sup>, 2012.

**Wells JA**, Berger BB, Gonzales C, Gonzales BH, Johnson DL, Sippy BD, Soni M. Multicenter phase 1 clinical trial targeting tissue factor for the treatment of neovascular AMD. American Academy of Ophthalmology annual meeting, Chicago IL, Nov 11<sup>th</sup>, 2012.

### **PUBLICATIONS: Author or Writing Committee**

Bechara SJ, Grossniklaus HE, Waring GO, **Wells JA.** Keratoconus associated with posterior polymorphous dystrophy. *Am J Ophthalmol* 1991; 112: 729-31.

**Wells J**, Wroblewski J, Keen J, et al. Mutations in the human retinal degeneration slow (RDS) gene can cause either retinitis pigmentosa or macular dystrophy. *Nature Genetics* 1993; 3: 213-17.

Piguet B, **Wells JA**, Palmvang I, et al. Age-related Bruch's membrane change: a clinical study of the relative role of heredity and the environment. *Br J Ophthalmol* 1993; 77: 400-03.

Wroblewski JJ, **Wells JA**, Eckstein A, et al. Macular dystrophy associated with mutations at codon 172 in the human retinal degeneration slow (RDS) gene. *Ophthalmology* 1994; 101: 12-22.

**Wells JA**, Ellerine N, Fernhoff P, Waring GO. Corneal opacities in spondyloepiphyseal dysplasia tarda. *Cornea* 1994; 13: 280-83.



Wroblewski JJ, **Wells JA**, Eckstein A, et al. Ocular findings associated with a three base pair deletion in the peripherin-RDS gene in autosomal dominant retinitis pigmentosa. *Br J Ophthalmol* 1994; 78: 831-36.

Holz FG, Wolfensberger TJ, Piguet B, **Wells JA**, et al. Bilateral macular drusen in age-related macular degeneration: prognosis and risk factors. *Ophthalmology* 1994; 101: 1522-8.

**Wells JA**, Murthy R, Chibber R, Nunn A, Molinatti PA, Kohner EM, Gregor ZJ. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. *Br J Ophthalmol* 1996; 80: 363-366.

Pitts JF, Schwartz SD, **Wells J**, Gregor ZJ. Indirect argon laser drainage of subretinal fluid. *Eye*. 1996; 10 (Pt 4): 465-468.

**Wells JA**, Gregor ZJ. Surgical treatment of full-thickness macular holes using autologous serum. *Eye*. 1996; 10 (Pt 5): 593-599.

Ezra E, **Wells JA**, Gray RH, Kinsella FM, Orr GM, Grego J, Arden GB, Gregor ZJ. Incidence of idiopathic full-thickness macular holes in fellow eyes. A five-year prospective natural history study. *Ophthalmology*. 1998 Feb; 105 (2): 353-359.

Eckstein MA, **Wells JA**, Gregor ZJ. Surgical removal of non-age-related subfoveal choroidal neovascular membranes. *Eye*. 1998; 12 (Pt 5): 775-780.

Ezra E, Gregor ZJ; **Moorfields Macular Hole Study Group**. Surgery for idiopathic full-thickness macular hole: two-year results of a randomized clinical trial comparing natural history, vitrectomy, and vitrectomy plus autologous serum: Moorfields Macular Hole study Group Report No. 1. *Arch Ophthalmol*. 2004 Feb;122(2):224-36

Diabetic Retinopathy Clinical Research Network, Danis RP, Glassman AR, Aiello LP, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Kinyoun JL, Murtha TJ, Topping TM,

Shami M, Sharuk GS, **Wells JA 3<sup>rd</sup>**. Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema. *Arch Ophthalmol*. 2006 Dec;124(12):1701-7.

Diabetic Retinopathy Clinical Research Network, Brucker AJ, Qin H, Antoszyk AN, Beck RW, Bressler NM, Browning DJ, Elman MJ, Glassman AR, Gross JG, Kollman C, **Wells JA 3<sup>rd</sup>**. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. *Arch Ophthalmol*. 2009 Feb;127(2):132-40.

Wroblewski JJ, **Wells JA 3<sup>rd</sup>**, Adamis AP, Buggage RR, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Altaweel MM; Pegaptanib in Central Retinal Vein Occlusion Study Group. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. *Arch Ophthalmol*. 2009 Apr;127(4):374-80.

Wroblewski JJ, **Wells JA 3<sup>rd</sup>**, Gonzales CR. Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion. *Am J Ophthalmol*. 2010 Jan;149(1):147-54. Epub 2009 Oct 28.

Bressler SB, Qin H, Beck RW, Chalam KV, Kim JE, Melia M, **Wells JA 3<sup>rd</sup>**; Diabetic Retinopathy Clinical Research Network. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. *Arch Ophthalmol*. 2012 Sep;130(9):1153-61. PubMed [citation] PMID: 22965591, PMCID: PMC3543147

Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, **Wells J**, Martin DF. Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Baseline predictors for one-year visual outcomes with ranibizumab or

John Anderson Wells, III

bevacizumab for neovascular age-related macular degeneration. *Ophthalmology*. 2013 Jan;120(1):122-9. doi: 10.1016/j.ophtha.2012.07.042. Epub 2012 Oct 6. PubMed [citation] PMID: 23047002, PMCID: PMC3536921

**Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW.** Aflibercept, Bevacizumab, or ranibizumab for diabetic macular edema. *N Engl J Med*, 2015 Mar 26; 372 (13): 1193-203. Doi: 10.1056/NEJMoa1414264. PMID: 25692915

**Wells JA, Glassman AS, Jampol LM, et al., for the Diabetic Retinopathy Clinical Research Network.** Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. *JAMA Ophthalmol*. doi:10.1001/jamaophthalmol.2015.4599  
Published online November 25, 2015.

Jaffe GJ, Elliott D, **Wells JA**, Prenner JL, Papp A, Patel S. A Phase 1 Study of Intravitreal E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration. *Ophthalmology* 2016;123:78-85

**Wells JA, Glassman AR, Ayala AR, et al. for the Diabetic Retinopathy Clinical Research Network.** Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. *Ophthalmol*, <http://dx.doi.org/10.1016/j.ophtha.2016.02.022> *Ophthalmol*. 2016 Feb 27. pii: S0161-6420(16)00206-2. doi: 10.1016/j.ophtha.2016.02.022. [Epub ahead of print]

#### **PUBLICATIONS: Clinical Trial Investigator or Group Member**

Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; **VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group.** Pegaptanib for neovascular age-related macular degeneration. *N Engl J Med*. 2004; 351: 2805-16.

**The VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group.** Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with Pegaptanib Sodium: An Exploratory analysis. *Retina* 2005; 25: 815-27.

**Macugen Diabetic Retinopathy Study Group.** A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. *Ophthalmology* 2005; 112: 1747-57.

**Macugen Diabetic Retinopathy Study Group.** Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. *Ophthalmology* 2005; 113: 23-28.

Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, for the **ANCHOR Study Group.** Ranibizumab versus Verteporfin for age-related macular degeneration. *N Engl J Med* 2006;355:1432-44.

**Diabetic Retinopathy Clinical Research Network.** Comparison of the modified early treatment diabetic retinopathy study and mild macular laser grid photocoagulation strategies for diabetic macular edema. *Arch Ophthalmol* 2007; 125: 469-80.

**Diabetic Retinopathy Clinical Research Network.** The risk of endophthalmitis following intravitreal injection in the DRCRnet and SCORE clinical trials. *Am J Ophthalmol* 2007; 114: 454-6.

**Diabetic Retinopathy Clinical Research Network.** Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. *Ophthalmology* 2007; 114: 525-36.

**Diabetic Retinopathy Clinical Research Network,** Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. *Ophthalmology*.2007 Oct;114(10):1860-7.

Ip MS, Bressler SB, Antoszyk AN, Flaxel CJ, Kim JE, Friedman SM, Qin H; **Diabetic Retinopathy Clinical Research Network.** A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. *Retina*.2008 Jul-Aug;28(7):919-30.

**Diabetic Retinopathy Clinical Research Network.** A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. *Ophthalmology*.2008 Sep;115(9):1447-9.e1-10.

Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H; **Diabetic Retinopathy Clinical Research Network.** Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. *Ophthalmology*. 2008 Aug;115(8):1366-71, 1371.e1.

**Diabetic Retinopathy Clinical Research Network.** A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. *Ophthalmology*. 2008 Sep;115(9):1447-9, 1449.e1-10.

Bressler NM, Edwards AR, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Danis RP, Elman MJ, Friedman SM, Glassman AR, Gross JG, Li HK, Murtha TJ, Stone TW, Sun JK;

**Diabetic Retinopathy Clinical Research Network.** Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. *Am J Ophthalmol*.2008 May;145(5):894-901.

SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design. Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, Antoszyk AN; **SCORE Study Investigator Group.** *Am J Ophthalmol*. 2009 Nov;148(5):725-732.e7. doi: 10.1016/j.ajo.2009.06.004. Epub 2009 Aug 11

Browning DJ, Apte RS, Bressler SB, Chalam KV, Danis RP, Davis MD, Kollman C, Qin H, Sadda S, Scott IU; **Diabetic Retinopathy Clinical Research Network.** Association of the extent of diabetic macular edema as assessed by optical coherence tomography with visual acuity and retinal outcome variables. *Retina*.2009 Mar;29(3):300-5.

**Diabetic Retinopathy Clinical Research Network (DRCR.net),** Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C. Three-year follow up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. *Arch Ophthalmol*.2009 Mar;127(3):245-51.

**The SCORE Study Research Group.** A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein Occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 5. Arch Ophthalmol, Sep 2009; 127: 1101 - 1114.

**The SCORE Study Research Group.** A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Standard Care to Treat Vision Loss Associated With Macular Edema Secondary to Branch Retinal Vein Occlusion: The Standard Care vs corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 6. Arch Ophthalmol, Sep 2009; 127: 1115 - 1128.

**Diabetic Retinopathy Clinical Research Network.** The course of response to focal/grid photocoagulation for diabetic macular edema. Retina.2009 Nov-Dec;29(10):1436-43

Bhavsar AR, Googe JM Jr, Stockdale CR, Bressler NM, Brucker AJ, Elman MJ, Glassman AR; **Diabetic Retinopathy Clinical Research Network.** The Risk of Endophthalmitis Following Intravitreal Injection in the DRCR.net Laser-Ranibizumab-Triamcinolone Clinical Trials. Arch Ophthalmol. 2009 Dec;127(12):1581-3.

**Diabetic Retinopathy Clinical Research Network (DRCR.net),** Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C. Three-year follow up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol.2009 Mar;127(3):245-51.

Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; **OZURDEX GENEVA Study Group.** Ophthalmology. 2010 Jun;117(6):1134-1146.e3. doi: 10.1016/j.ophtha.2010.03.032. Epub 2010 Apr 24

Aiello LP, Edwards AR, Beck RW, Bressler NM, Davis MD, Ferris FL, Glassman AR, Ip MS, Miller KM, for the **Diabetic Retinopathy Clinical Research Network.** Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2010 May;117(5):946-953.

**Diabetic Retinopathy Clinical Research Network** Writing Committee on behalf of the DRCR.net, Haller JA, Qin H, Apte RS, Beck RW, Bressler NM, Browning DJ, Danis RP, Glassman AR, Googe JM, Kollman C, Lauer AK, Peters MA, Stockman ME. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2010 Jun;117:1087-1093.e3

**Diabetic Retinopathy Clinical Research Network.** Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema. Retina. 2010 Oct;30(9):1488-95.

**Diabetic Retinopathy Clinical Research Network.** Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010 June;117(6):1064-1077.e35

John Anderson Wells, III

Friberg TR, Tolentino M for the **LEVEL Study Group**. Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration. *Br J Ophthalmol* 2010 94: 1611-1617.

**The CATT Research Group**. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. *N Engl J Med* 2011;10.1056/NEJMe1103334 NEJM.org.

**The Diabetic Retinopathy Clinical Research Network**. Expanded 2-year Follow-up of a Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. *Ophthalmology*.2011 April; 118(4):609-14

**Diabetic Retinopathy Clinical Research Network**. Randomized Trial Evaluating Short-Term Effects of Intravitreal Ranibizumab or Triamcinolone Acetonide on Macular Edema Following Focal/Grid Laser for Diabetic Macular Edema in Eyes Also Receiving Panretinal Photocoagulation. *Retina*.E-Print.

Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS; **Macugen 1013 Study Group**. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. *Ophthalmology*. 2011 Jun;118(6):1107-18. doi: 10.1016/j.ophtha.2011.02.045. Epub 2011 May 6. PubMed [citation] PMID: 21529957

Gangaputra S, Almkhatar T, Glassman AR, Aiello LP, Bressler N, Bressler SB, Danis RP, Davis MD; **Diabetic Retinopathy Clinical Research Network**. Comparison of film and digital fundus photographs in eyes of individuals with diabetes mellitus. *Invest Ophthalmol Vis Sci*. 2011 Aug 3;52(9):6168-73. doi: 10.1167/iovs.11-7321. PubMed [citation] PMID: 21571677, PMCID: PMC3176025

Schmitz-Valckenberg S, Alten F, Steinberg JS, Jaffe GJ, Fleckenstein M, Mukesh BN, Hohman TC, Holz FG; **Geographic Atrophy Progression (GAP) Study Group**. Reticular drusen associated with geographic atrophy in age-related macular degeneration. *Invest Ophthalmol Vis Sci*. 2011 Aug 24;52(9):5009-15. doi: 10.1167/iovs.11-7235. PubMed [citation] PMID: 21498612

Loftus JV, Sultan MB, Pleil AM; **Macugen 1013 Study Group**. Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham. *Invest Ophthalmol Vis Sci*. 2011 Sep 29;52(10):7498-505. doi: 10.1167/iovs.11-7613. PubMed [citation] PMID: 21896838

Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM; Ozurdex **GENEVA Study Group**, Li J. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. *Ophthalmology*. 2011 Dec;118(12):2453-60. doi: 10.1016/j.ophtha.2011.05.014. Epub 2011 Jul 20. PubMed [citation] PMID: 21764136

Comparison of Age-related Macular Degeneration Treatments Trials (**CATT**) **Research Group**, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. *Ophthalmology*. 2012 Jul;119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053. Epub 2012 May 1. PubMed [citation] PMID: 22555112, PMCID: PMC3389193

Mauschitz MM, Fonseca S, Chang P, Göbel AP, Fleckenstein M, Jaffe GJ, Holz FG, Schmitz-Valckenberg S; **GAP Study Group**. Topography of geographic atrophy in age-

John Anderson Wells, III

related macular degeneration. *Invest Ophthalmol Vis Sci.* 2012 Jul 26;53(8):4932-9. PubMed [citation] PMID: 22661483

Grunwald JE, Daniel E, Ying GS, Pistilli M, Maguire MG, Alexander J, Whittock-Martin R, Parker CR, Sepielli K, Blodi BA, Martin DF for the CATT Research Group. Photographic assessment of baseline fundus morphologic features in the Comparison of Age-related Macular Degeneration Treatments Trials. *Ophthalmology.* 2012 Aug;119(8):1634-41.

Chalam KV, Bressler SB, Edwards AR, Berger BB, Bressler NM, Glassman AR, Grover S, Gupta SK, Nielsen JS; **Diabetic Retinopathy Clinical Research Network**. Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg Spectralis optical coherence tomography. *Invest Ophthalmol Vis Sci.* 2012 Dec 13;53(13):8154-61. doi: 10.1167/iovs.12-10290. PubMed [citation] PMID: 23132803, PMCID: PMC3522439

Chew EY, Clemons T, SanGiovanni JP, et al; AREDS2 Research Group. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). *Ophthalmology.* 2012;119(11):2282-2289.

DeCroos FC, Toth CA, Stinnett SS, Heydary CS, Burns R, Jaffe GJ, for the CATT Research Group. Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. *Ophthalmology.* 2012 Dec; 119(12):2549-57.

Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Callanan DG, Kim IK, Klein ML, Maguire MG, Martin DF, for the Comparison of Age-related Macular Degeneration Treatments Trials Group. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). *Ophthalmology.* 2013 Mar;120(3):593-9.

Busbee BG, Ho AC, Brown DM, Heier JS, Suner IJ, Li Z, Rubio RG, Lai P; HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg and 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. *Ophthalmology.* 2013 Mar;120(5):1046-56.

Steinberg JS, Auge J, Jaffe GJ, Fleckenstein M, Holz FG, Schmitz-Valckenberg S; **GAP Study Group**. Longitudinal analysis of reticular drusen associated with geographic atrophy in age-related macular degeneration. *Invest Ophthalmol Vis Sci.* 2013 Jun 10;54(6):4054-60. doi: 10.1167/iovs.12-11538. PubMed [citation] PMID: 23633663

Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. *JAMA.* 2013;309(19): 2005-2015.

Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, Grunwald JE, Huang J, for the Comparison of Age-related Macular Degeneration Treatments Trials Group. Macular morphology and visual acuity in the Comparison of Age-related Macular Degeneration Treatments Trials. *Ophthalmology.* 2013 Sep;120(9):1860-70.

Maguire MG, Daniel E, Shah AR, Grunwald JE, Hagstrom SA, Avery RL, Juang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF for the Comparison of Age-related Macular Degeneration Treatments Trials Group. Incidence of choroidal

John Anderson Wells, III

neovascularization in the fellow eye in the Comparison of Age-related Macular Degeneration Treatments Trials. *Ophthalmology*. 2013 Oct;120 (10):2035-41.

Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, Juang J, Ying GS, Hagstrom SA, Winter K, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials. *Ophthalmology* 2013 Dec 3 Epub ahead of print.

Chew EY, Clemons TE, SanGiovanni JP, et al; Age-Related Eye Disease Study 2 (AREDS2) Research Group. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. *JAMA Ophthalmol*. 2014;132(2):142-149.

Bonds DE, Harrington M, Worrall BB, et al; Writing Group for the AREDS2 Research Group. Effect of long-chain #3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. *JAMA Intern Med*. 2014;174(5):763-771.

Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF, for the Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials. *Ophthalmology* 2014;121:150-161.

Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying G, Hagstrom SA, Winter K, Maguire MG for the Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials. *Ophthalmology* 2014;121:656-666.

Chew EY, Clemons TE, Agron E, Launer LJ, Grodstein F, Bernstein PS, for the Age-Related Eye Disease Study 2 (AREDS2) Research Group. Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function The AREDS2 Randomized Clinical Trial. *JAMA*. 2015;314(8):791-801. doi:10.1001/jama.2015.9677

## **CLINICAL TRIALS: PRINCIPAL INVESTIGATOR**

### **1999-2000** Principal Investigator

An Open-Label, Multicentre, Safety Study of the Treatment of Predominantly Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age Related Macular Degeneration (AMD) using Photodynamic Therapy with Verteporfin for Injection. Verteporfin in age-related macular degeneration (VAM) study. Sponsor: Novartis

### **2001-2006** Principal Investigator

A phase II/III randomized, double-masked, controlled, dose-ranging, multi-center comparative trial, in parallel groups, to establish the safety and efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks, in patients with exudative age-related macular degeneration (AMD). (VISION Study) Sponsor: Eyetech Pharmaceuticals, Inc.

### **2002-2005** Principal Investigator

John Anderson Wells, III

A phase II randomized, controlled, double-masked, dose-finding, multi-center, comparative trial, in parallel groups, to establish the safety and preliminary efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer), given every 6 weeks for 12 to 30 weeks to patients with clinically significant macular edema (CSME) involving the center of the macula. Sponsor: Eyetech Pharmaceuticals, Inc.

**2002-2004** Principal Investigator

A randomized, double-masked, multi-center trial of the safety, tolerability and pharmacokinetics of 1mg/eye and 3 mg/eye intravitreal injections of pegaptanib sodium

(anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks, in patients with exudative age-related macular degeneration (AMD). Sponsor: Eyetech Pharmaceuticals, Inc.

**2003-2004** Principal Investigator

An open-label, multi-center trial of the safety, tolerability and pharmacokinetics of 3 mg/eye intravitreal injections of pegaptanib sodium (Anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks, in patients with exudative age-related macular degeneration (AMD). Sponsor: Eyetech Pharmaceuticals

**2004-2008** Principal Investigator

An evaluation of efficacy and safety of posterior juxtасlеral administrations of anecortave acetate for depot suspension (15 mg or 30 mg) versus sham administration in patients (enrolled in Study “A” or Study “B”) at risk for developing sight-threatening choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD). (AART) Sponsor: Alcon

**2004-2008** Principal Investigator

A six-month phase III, multicenter, masked, randomized, sham-controlled trial (with six-month open-label extension) to assess the safety and efficacy of 700 µg and 350µg dexamethasone posterior segment drug delivery system (DEX PS DDS Applicator System) in the treatment of patients with macular edema following central retinal vein occlusion or branch retinal vein occlusion (POSURDEX). Sponsor: Allergan

**2004-2008** Principal Investigator

Standard care versus corticosteroid for retinal vein occlusion (SCORE).

**2004-2005** Principal Investigator

A Phase II prospective, randomized, double-masked, dose-ranging, multi-center trial to assess the effect of pegaptanib sodium on macular thickening measured by OCT in patients with exudative subfoveal age-related macular degeneration. Sponsor: Eyetech

**2004-2005** Principal Investigator

A Phase II randomized, double-masked, multi-center trial, in parallel groups, to compare the safety, efficacy, and pharmacokinetics of intravitreal injections of pegaptanib sodium to sham injection for 30 weeks in patients with recent vision loss due to macular edema secondary to CRVO. Sponsor: Eyetech

**2004-2005** Principal Investigator

An open label, non-comparative protocol for the use of pegaptanib sodium injection every 6 weeks in patients with exudative age-related macular degeneration. Sponsor: Eyetech

**2004-2006** Principal Investigator



John Anderson Wells, III

A Phase 1/2, randomized, masked, placebo-controlled, single and multiple-dose, sequential dose-escalation study of the safety and efficacy of AG-013958 in subjects with subfoveal choroidal neovascularization associated with age-related macular degeneration (A4321001). Sponsor: Pfizer

**2005** Principal Investigator

Temporal variation in optical coherence tomography measurements of retinal thickening in diabetic macular edema. Sponsor: Diabetic Retinopathy Clinical Research Network

**2005-2007** Principal Investigator

A phase 2/3 randomized, controlled, double-masked, multi-center, comparative dose-finding trial, in parallel groups, to compare the safety and efficacy of intravitreal injections of 0.3, 0.03, or 0.003 mg pegaptanib sodium (Macugen®), given as often as every 6 weeks for 3 years, to sham injections, in subjects with diabetic macular edema (DME) involving the center of the macula. Sponsor: Eyetech

**2005-2007** Principal Investigator

Diabetic Retinopathy Clinical Research Network: An observational study of the development of diabetic macular edema following scatter laser photocoagulation.

**2006-2007** Principal Investigator

A phase II, pharmacokinetic, randomized, double-masked, controlled, dose comparison study of Cand5 for intravitreal injection for the treatment of diabetic macular edema. Sponsor: Opko

**2006-2008** Principal Investigator

Open label Macugen for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO). Sponsor: Pfizer/Eyetech

**2006-2008** Principal Investigator

A phase IV, open label, multi-center trial of maintenance intravitreal injections of Macugen® (Pegaptanib sodium) given every 6 weeks for 48 weeks in subjects with subfoveal neovascular age-related macular degeneration initially treated with a modality resulting in maculopathy improvement (The **LEVEL** Study). Sponsor: Eyetech

**2007-2013** Principal Investigator

Age-related Eye Diseases Study 2 (**AREDS2**): A multi-center, randomized trial of lutein, zeaxanthin, and Omega-3 Long-Chain Polyunsaturated Fatty Acids (Docosahexaenoic Acid [DHA] and Eicosapentaenoic Acid [EPA]) in age-related macular degeneration . Sponsor: National Eye Institute

**2007-2008** Principal Investigator

A trial to assess the safety and tolerability of repeated doses of intravitreal administration of two VEGF trap formulations in subjects with neovascular age related macular degeneration (0603). Sponsor: Regeneron

**2007-2010** Principal Investigator

A phase II multicenter, randomized, double-masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of geographic atrophy in subjects with age-related macular degeneration. Sponsor: Sirion

**2007-2009** Principal Investigator

A phase 3, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered 8 or 12 weeks as maintenance therapy following three injections of Lucentis® compared with Lucentis® monotherapy every 4 weeks in patients with exudative age-related macular degeneration (Cobalt). Sponsor: Opko

**2007-2009** Principal Investigator

Diabetic Retinopathy Clinical Research Network: Intravitreal ranibizumab or triamcinolone acetonide as adjunctive treatment to panretinal photocoagulation for proliferative diabetic retinopathy. (Protocol J)

**2008-2009** Principal Investigator

A phase 1, single ascending dose trial to establish the safety, tolerability and pharmacokinetic profile of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) monotherapy and of E10030 given in combination with Lucentis 0.5 mg/eye in subjects with age-related macular degeneration. Sponsor: Ophthotech

**2008-2009** Principal Investigator

A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic profile of Single and Repeated Doses of JSM6427 Following Administration by Intravitreal Injection in Patients with ° Neovascular Age-Related Macular Degeneration (AMD). Sponsor: Jerini Ophthalmics

**2008-2009** Principal Investigator

The natural history of geographic atrophy progression (**GAP**) secondary to age-related macular degeneration. Sponsor: Alcon

**2008-2011** Principal Investigator

An open-label, long-term, safety, and tolerability study of intravitreal VEGF Trap-EYE in subjects with neovascular age-related macular degeneration (0702). Sponsor: Regeneron

**2008-2011** Principal Investigator

Comparison of age-related macular degeneration treatment trials (**CATT**).

**2009-2012** Principal Investigator

The safety and efficacy of AL-8309B ophthalmic solution for the treatment of geographic atrophy secondary to age-related macular degeneration (**GATE**). Sponsor: Alcon

**2010-2012** Principal Investigator

A phase 2, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) given in combination with Lucentis® in subjects with neovascular age-related macular degeneration. Sponsor: Ophthotech.

**2010-2013** Principal Investigator

A Phase IIa, Safety and Preliminary Effects Study of WST11<sub>SEP</sub>(Stakel(r))-Mediated Vascular-Targeted Photodynamic (VTP) Therapy in Subjects with Choroidal Neovascularization (CNV) Associated with Age-Related Macular Degeneration (AMD). Sponsor: Steba

**2011-2012** Principal Investigator A phase 1/2 trial to investigate the safety and tolerability of single and repeated doses of hI-CON™ following administration by intravitreal injection in subjects with neovascular age-related macular degeneration . Sponsor: Iconic

**2011-2015** Principal Investigator  
Diabetic Retinopathy Clinical Research Network: Effect of Diabetes Education during Retinal Ophthalmology Visits on Diabetes Control. Protocol M

**2012-2015** Principal Investigator  
Diabetic Retinopathy Clinical Research Network: A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema. Protocol T

**2011-present** Principal Investigator  
Diabetic Retinopathy Clinical Research Network: Genes in Diabetic Retinopathy Project

**2011-2015** Principal Investigator  
A Phase 2a, Multi-center , Masked, Randomized, Comparator-controlled Study Evaluating iSONEP(Sonepcizumab LT 1009) as Either Monotherapy or Adjunctive Therapy to Lucentis or Avastin Versus Lucentis or Avastin Alone for the treatment of Subjects with Choroidal Neovascularization Secondary to Age-related Macular Degeneration (Nexus). Sponsor LPath

**2012-2015** Principal Investigator  
Multi-Center Randomized, Single Masked Phase 2 Study of Intravitreal Injections of SIROLIMUS in the Treatment of Central Geographic Atrophy associated with Age- Related Macular Degeneration (SIROLIMUS). Sponsor: NEI

**2011-2013** Principal Investigator  
A Multi-Center Randomized, Sham-controlled, Repeat –Dose Study to Assess the Safety, Tolerability, Serum Pharmacokinetics, and Efficacy of Intravitreal LFG 316 in Patients with Neovascular Age-Related macular degeneration (LFG316A). Sponsor : Novartis

**2013-present** Principal Investigator  
A Phase 3 Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreal Administration of Fovista (Anti-PDGF-B Pegylated Aptamer) Administered in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects With Neovascular Age-Related Macular Degeneration (OPH1003) Sponsor: Ophthotech

**2014- present** Principal Investigator  
An Open label, Single Ascending Dose Study to Investigate the Safety, Efficacy and Pharmacodynamics of a Novel Plasma Kallikrein Inhibitor Administered by Intravitreal Injection in Subjects with Central Involved Diabetic Macular Edema and Reduced Vision. Sponsor: KalVista

**2014-2016** Principal Investigator  
Protocol PAN-01-101 A Phase 1 Open-Label, Multi-Center Trial with Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients with Neovascular Age-Related Macular Degeneration (AMD). Sponsor: PanOptica

**2015-present** Principal Investigator

John Anderson Wells, III

GX29633- Proxima A Multicenter, Prospective Epidemiologic Study of the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration. Sponsor: Genentech

**2015-2016** Principal Investigator

Protocol Number: IT-002 A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients with Choroidal Neovascularization Secondary to Age related Macular Degeneration. Sponsor: Iconic

**2015-present** Principal Investigator

Diabetic Retinopathy Clinical Research Network (AA) Peripheral Diabetic Retinopathy (DR) Lesions on Ultrawide-field Fundus Images and Risk of DR Worsening Over Time.

**2016-present** Principal Investigator

Diabetic Retinopathy Clinical Research Network (W) Intravitreal Anti-VEGF Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk.

**2016-present** Principal Investigator

OPT-302-1001 A Phase 1/2a Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 in combination with Ranibizumab in subjects with wet AMD. Sponsor: Ophthea

## **Clinical Trials: Investigator**

**2002** Collaborating Physician

Study of Diabetic Retinopathy in the Family Investigation of Nephropathy and Diabetes (FIND)

**2003-2006** Investigator

A phase III, multicenter, randomized, double-masked, active treatment-controlled study of the efficacy and safety of rhuFab (ranibizumab) compared with Verteporfin (Visudyne®) photodynamic therapy in subjects with predominantly classic subfoveal neovascular age-related macular degeneration (ANCHOR). Sponsor: Genentech

**2003-2006** Investigator

Diabetic Retinopathy Clinical Research Network Protocol 1-A: A pilot study of laser photocoagulation for diabetic macular edema.

**2004-2008** Investigator

Diabetic Retinopathy Clinical Research Network Protocol II: A randomized trial comparing intravitreal corticosteroids and laser photocoagulation for diabetic macular edema.

**2005-2007** Investigator

John Anderson Wells, III

An open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) who have completed the treatment phase of a Genentech sponsored ranibizumab study. Sponsor: Genentech

**2005-2008 Investigator**

Diabetic Retinopathy Clinical Research Network: Evaluation of vitrectomy for diabetic macular edema study

**2005-2008 Investigator**

A 24-month randomized, double-masked, sham controlled, multicenter, phase IIIB study comparing photodynamic therapy with verteporfin (Visudyne®) plus two different dose regimens of intravitreal triamcinolone acetonide (1mg and 4mg) versus Visudyne® plus intravitreal pegaptanib (Macugen®) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

**2005-2008 Investigator**

A Phase IIIB, single-masked, multicenter, randomized study to evaluate the safety and tolerability of Ranibizumab in naive and previously treated subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Sponsor: Genentech

**2006 Investigator**

A retrospective medical chart review of neovascular age-related macular degeneration (AMD) subjects treated with Macugen monotherapy. Sponsor: Eyetech Pharmaceuticals

**2006-2007 Investigator**

Clinical evaluation of the safety of next generation ophthalmic irrigating solution (NGOIS) compared to BSS Plus for use during surgery for removal of epimacular membrane with vitrectomy. Sponsor: Alcon

**2006-2007 Investigator**

Diabetic Retinopathy Clinical Research Network: A phase 2 evaluation of anti-VEGF therapy for diabetic macular edema: Bevacizumab (Avastin)

**2007-2008 Investigator**

DNA repository study in association with study FVF3426g (An open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) who have completed the treatment phase of a Genentech sponsored ranibizumab study)

**2007-2009 Investigator**

A 24-month randomized, double masked, controlled, multicenter, phase IIIB study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with ranibizumab (Lucentis™) versus ranibizumab (Lucentis™) monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (DENALI). Sponsor: Novartis

**2007-2012 Investigator**

John Anderson Wells, III

A phase III, double-masked, multi-center randomized, sham-controlled study of the efficacy and safety of ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes mellitus (RISE and RIDE). Sponsor: Genentech

**2007-2011 Investigator**

A randomized, double-masked, active-controlled phase III study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF trap in subjects with neovascular age-related macular degeneration (0605). Sponsor: Regeneron

**2007-2013 Investigator**

Diabetic Retinopathy Clinical Research Network: Intravitreal ranibizumab or triamcinoloneacetonide in combination to laser photocoagulation for diabetic macular edema. (Protocol I)

**2008-2009 Investigator**

A phase III, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to central retinal vein occlusion (CRUISE). Sponsor: Genentech

**2008-2009 Investigator**

A phase III, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to branch retinal vein occlusion (BRAVO). Sponsor: Genentech

**2008-present Investigator**

Intravitreal bevacizumab (Avastin™) injections versus conventional laser for vision-threatening retinopathy of prematurity: a prospective, randomized, non-blinded, controlled, multi-center trial.

**2008-2010 Investigator**

A phase 2, randomized, double-masked, placebo-controlled, dose-ranging clinical study to assess the safety and efficacy of subconjunctival injections of sirolimus in patients with diabetic macular edema secondary to diabetic retinopathy. Sponsor: Macusight

**2009-2011 Investigator**

A double-masked, randomized, controlled study of the safety, tolerability and biological effect of repeated intravitreal administration of VEGF Trap-Eye in patients with diabetic macular edema (DME),(0706). Sponsor: Regeneron

**2009-2011 Investigator**

A randomized, double masked, controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in Subjects with macular edema secondary to central retinal vein occlusion (CRVO), (0819). Sponsor: Regeneron

**2009-2012 Investigator**

A phase III, double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5mg and 2.0mg ranibizumab administered monthly or on an as-needed basis (PRN) in patients with subfoveal neovascular age-related macular degeneration (HARBOR). Sponsor: Genentech

John Anderson Wells, III

**2010-2012** Investigator

A phase I, double-masked, placebo-controlled study evaluating the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple escalating dosages of RN6G in subjects with advanced dry, age-related macular degeneration (AMD) including geographic atrophy. Sponsor: Pfizer

**2010** Investigator

VEGF Trap-Eye pharmacokinetic sub-study VGFT-OD-0706.PK. Sponsor: Regeneron

**2010-2012** Investigator

DNA repository substudy in association with ranibizumab study FVF4579g: a phase III, double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5mg and 2.0mg ranibizumab administered monthly or on an as-needed basis (PRN) in patients with subfoveal neovascular age-related macular degeneration. Sponsor: Genentech

**2010-2013** Investigator

An open-label, long-term, safety and tolerability extension study of intravitreal VEGF Trap-EYE in subjects with neovascular age-related macular degeneration (0910). Sponsor: Regeneron

**2011-2012** Investigator

A phase IB/II, multicenter, randomized, single-masked, sham injection-controlled study of safety, tolerability, and evidence of activity of FCFD4514S intravitreal injections administered monthly or every other month to patients with geographic atrophy. Sponsor: Genentech

**2011-2012** Investigator

A multi-center randomized study evaluating dosing regimens for treatment with intravitreal ranibizumab injections in subjects with macular edema following retinal vein occlusion (SHORE). Sponsor: Genentech

**2011-2016** Investigator

A phase III, multinational, multicenter, randomized, double-masked, study assessing the safety and efficacy of intravitreal injections of DE-109 (three doses) for the treatment of active, non-infectious uveitis of the posterior segment of the eye. Sponsor: Santen

**2011-2014** Investigator

Regeneron 1009.1 A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema (1009). Sponsor: Regeneron

**2013-present** Investigator

A phase IIIb, multicenter, randomized, controlled study of the safety, tolerability and efficacy of intravitreal injections of 0.5mg ranibizumab given monthly compared to a Treat and Extend protocol in patients with wet age-related macular degeneration (TRES AMD). Sponsor: Genentech

**2012-2014** Investigator

John Anderson Wells, III

An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients with Neovascular Age-Related Macular Degeneration (1124). Sponsor: Regeneron

**2012-present** Investigator

A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion (1027). Sponsor: Regeneron

**2012-2013** Investigator

Phase 2 Multi-Center, Randomized, Double Masked, Placebo-Controlled, Multi-Dose study To investigate the efficacy, safety pharmacokinetics and pharmacodynamics of RN6G (04382923) in subjects with geographic atrophy secondary to age-related macular degeneration. (B1181003). Sponsor: Pfizer

**2012-2014** Investigator

A Multicenter, Open-Label, Randomized Study Comparing the Efficacy and Safety of 700ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients with Diabetic Macular Edema (206207-024). Sponsor: Allergan

**2013-2015** Investigator

SCORE2: Study of Comparative Treatments for Retinal Vein Occlusion 2 [SCORE2]: a multicenter, prospective randomized non-inferiority trial of eyes with macular edema secondary to central retinal vein occlusion, comparing intravitreal bevacizumab every 4 weeks with intravitreal aflibercept every 4 weeks. Sponsor: NEI

**2013-present** Investigator

TREX DME-A phase I/II, open-label, multicenter, randomized, controlled study of the safety, tolerability and efficacy of intravitreal injections of 0.3 mg ranibizumab given monthly compared to a Treat and Extend protocol, with and without laser photocoagulation, in patients with Diabetic Macular Edema (T-REX-DME). Sponsor: Genentech

**2013-2016** Investigator

RANGE-Treat and extend therapy using intravitreal aflibercept (IAI) for previously treated patients exiting the wet age-related macular degeneration extension study (0910) RANGE. Sponsor: Regeneron

**2014-present** Investigator

GX29185 (Spectri) A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. Sponsor: Genentech

**2014-2015** Investigator

Allergan 150998-004- Evaluation of Abicipar Pegol (AGN-150998) in Patients with Decreased Vision Due to Diabetic Macular Edema.

**2015-present** Investigator

R2176-3-AMD-1417- (Capella) A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal



John Anderson Wells, III

REGN2176-3 in Patients with Neovascular Age-Related Macular Degeneration. Sponsor: Regeneron

**2016-present** Investigator

GX28228-(LADDER)-A Phase II, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration. Sponsor: Genentech

**2016-present** Investigator

VGFTe-OD-1411 (Panorama)-A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy. Sponsor: Regeneron

**2014-present** Investigator

Endurance-Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance Trial 2). Sponsor: Regeneron